Zipalertinib achieved a 30.2% intracranial objective response rate and 72.1% intracranial disease control rate in 43 evaluable patients with EGFR-mutated lung cancer and active CNS metastases. The Phase 2 findings support further development, although the treatment remains investigational.
Frontier Medicines will present its first Phase 1 clinical findings for FMC-376 at ESMO 2026, including preliminary responses in patients previously treated with KRAS G12C inhibitors. The investigational drug targets both active and inactive KRAS G12C, but detailed response rates and patient counts remain undisclosed ahead of the presentation.
ZAP Surgical has secured $36 million in financing led by Catalio Capital Management, following shipment of its 50th ZAP-X system and treatment of nearly 10,000 patients worldwide. The investment will support manufacturing expansion and broader access to self-shielded brain radiosurgery.
Faeth Therapeutics will present preclinical PIKTOR findings at ESMO 2026, including combinations with endocrine therapies and direct comparisons with gedatolisib in breast cancer models. The research supports an ongoing Phase 1b/2 trial, but human efficacy results in breast cancer are not yet available.
Gilead will present 28 studies at IDWeek 2026, covering Bixlenvo treatment outcomes, early real-world Yeztugo adoption and final Phase 1b findings for the investigational herpes medicine GS-1179. The programme examines how recently approved HIV treatments perform in practice while advancing a separate long-acting antiviral candidate.
Merck KGaA has agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, offering $20 per ADS. The transaction centers on divesiran, an RNA interference therapy that achieved an 88% response rate in Phase 2 polycythemia vera testing.
GE HealthCare has introduced LOGIQ Focus, a general imaging ultrasound system combining cSound Architecture with automated scanning and workflow tools. In a third-party abdominal imaging study, the system completed scans 26% faster than a comparator, while 90% of participating physicians rated image quality highly.
Sound Pharmaceuticals has presented a new Phase 3 analysis showing statistically significant low-to-mid-frequency hearing improvements with SPI-1005 in Ménière's disease. The company believes the findings support development for sudden sensorineural hearing loss, although that separate indication has not been established in a dedicated pivotal trial.
PharmaEssentia will present six studies examining treatment gaps and real-world BESREMi use in essential thrombocythemia and polycythemia vera. The findings include 55% two-year treatment persistence in first-line PV users and new molecular response data from Asian patient populations.
Vivacta Bio and Grit Bio have secured FDA orphan drug designation for GT801 in autoimmune hemolytic anemia. Early findings from two patients showed complete responses following treatment with the investigational in vivo CAR-T therapy, which uses targeted lipid nanoparticles to generate CD19-directed immune cells inside the body.